Bayesian Prediction of Down Syndrome Based on Maternal Age and Four Serum Markers

2004 ◽  
pp. 85-95
Author(s):  
Raquel Montes Diez ◽  
Juan M. Marin ◽  
David Rios Insua
Keyword(s):  
Down Syndrome ◽  
Maternal Age ◽  
Serum Markers ◽  
Bayesian Prediction

New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age

1998 ◽  
Vol 179 (6) ◽  
pp. 1627-1631 ◽  
Author(s):  
R.O. Bahado-Singh ◽  
A.U. Oz ◽  
E. Kovanci ◽  
O. Deren ◽  
J. Copel ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Maternal Age ◽  
Serum Markers ◽  
Screening Algorithm ◽  
Down Syndrome Screening

MATERNAL AGE AND DOWN SYNDROME

The Lancet ◽  
1978 ◽  
Vol 312 (8082) ◽  
pp. 213 ◽  
Author(s):  
M.A. Ferguson-Smith
Keyword(s):  
Down Syndrome ◽  
Maternal Age

The incidence of Down syndrome in northern Finland with special reference to maternal age

2008 ◽  
Vol 27 (3) ◽  
pp. 252-257 ◽  
Author(s):  
J. Leisti ◽  
L. Vahtola ◽  
S.-L. Linna ◽  
R. Herva ◽  
S.-L. Koskela ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Special Reference ◽  
Maternal Age

scholarly journals Fetal Down syndrome screening models for developing countries; Part II: Cost-benefit analysis

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Chanane Wanapirak ◽  
Piyaluk Buddhawongsa ◽  
Woraluck Himakalasa ◽  
Auttapan Sarnwong ◽  
Theera Tongsong
Keyword(s):  
Developing Countries ◽  
Down Syndrome ◽  
Maternal Age ◽  
Cost Benefit Analysis ◽  
National Policy ◽  
Cost Benefit ◽  
Second Trimester ◽  
Benefit Analysis ◽  
Low Resource ◽  
Secondary Screening

Abstract Background To identify the most cost-beneficial model as a national policy of screening and diagnosis of fetal Down syndrome (DS) in developing countries. Methods Cost-benefit analysis (CBA) was performed based on the effectiveness and probabilities derived from a large prospective study on MSS (maternal serum screening) among Thai population. Various models including maternal age alone, STS (second trimester screen), I-S (independent screen: first or second trimester screen depending on the time of first visit), C-S (contingent serum screen) plus STS, maternal age with NIPS (non-invasive prenatal test), STS alone with NIPS, I-S with NIPS, C-S plus STS with NIPS, and Universal NIPS were compared. Results I-S with NIPS as a secondary screening was most cost-beneficial (Benefit/Cost ratio 4.28). Cost-benefit is directly related to the costs of NIPS. Conclusion In addition to simplicity and feasibility, I-S with expensive NIPS as a secondary screening is the most cost-beneficial method for low resource settings and should be included in universal healthcare coverage as a national policy. This study could be a model for developing countries or a guideline for international health organizations to help low resource countries, probably leading to a paradigm shift in prenatal diagnosis of fetal DS in the developing world.

scholarly journals Maternal age specific risk rate estimates for Down syndrome among live births in whites and other races from Ohio and metropolitan Atlanta, 1970-1989.

1998 ◽  
Vol 35 (6) ◽  
pp. 482-490 ◽  
Author(s):  
C A Huether ◽  
J Ivanovich ◽  
B S Goodwin ◽  
E L Krivchenia ◽  
V S Hertzberg ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Maternal Age ◽  
Live Births ◽  
Specific Risk ◽  
Risk Rate
Sign in / Sign up

Export Citation Format

Share Document